OLEMA PHARMACEUTICALS INC

$4.27 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN), and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It was designed by based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumour shrinkage in several xenograft models, including a breast cancer brain metastasis model.

Stock Analysis

last close $4.06
1-mo return -10%
3-mo return 87.1%
avg daily vol. 576.93T
52-week high 32.19
52-week low 2
market cap. $164M
forward pe -
annual div. -
roe -34.6%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 87.2%
baraka

Subscribe now for daily local and international financial news

Subscribe